UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015997
Receipt number R000018592
Scientific Title WT1 peptide-based cancer vaccine for long-term maintenance of anti-tumor immunity
Date of disclosure of the study information 2014/12/20
Last modified on 2024/03/11 19:06:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

WT1 peptide-based cancer vaccine for long-term maintenance of anti-tumor immunity

Acronym

WT1 vaccine for long-term anti-tumor immunity

Scientific Title

WT1 peptide-based cancer vaccine for long-term maintenance of anti-tumor immunity

Scientific Title:Acronym

WT1 vaccine for long-term anti-tumor immunity

Region

Japan


Condition

Condition

solid tumor, malignant lymphoma, acute leukemia

Classification by specialty

Medicine in general Gastroenterology Hematology and clinical oncology
Gastrointestinal surgery Chest surgery Breast surgery
Oto-rhino-laryngology Orthopedics Urology
Neurosurgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate WT1-specific immune responses as a primary objective induced by WT1 peptide vaccine.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

DTH to WT1 peptide
Frequency of WT1 specific CTLs

Key secondary outcomes

Safety
1 Numbers and frequencies of adverse effects defined in NCI-CTCAE v4.0
2 Frequencies of hematological- and non-hematological adverse effects which result in suspension or withdrawal of WT1 peptide vaccine

Anti-tumor effects
Anti-tumor effects are evaluated at 3-6 months intervals by the method described elsewhere.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administration of WT1 peptide vaccine

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >=

Gender

Male and Female

Key inclusion criteria

1. diagnosed as having malignant tumor and treated with WT1 peptide vaccine in the following clinical trials in Osaka University Hospital
WT1 peptide vaccine for solid tumor
WT1 peptide vaccine for malignant lymphoma
WT1 peptide vaccine for hematologic malignancies after allogeneic stem cell transplantation phase I
Dose-increasing WT1 peptide vaccine for MDS phase I
2. Clinical usefulness of WT1 peptide vaccine was observed and its usefulness was accepted by a board

3.
Neutrophyl >= 1,000/ul no use of hematopoietic factors within 14days
SpO2>=94 percent (room air)
Plt>=50,000/ul no transfusion of platelet within 14days
Hb>=8g/dl no transfusion of RBC within 14 days
serm Crn <= 2.0mg/dL
serum T.Bil<=2.0 mg/dl
serum AST ALT <= 120U/L
4. Age: 20<=, <=85.
5.ECOG Performance Status (PS) 0-1
6. Written informed consent was obtained.

Key exclusion criteria

1. having severe infectious disease
2. having developed adverse effects (grade >=4) in the prior WT1 peptide vaccine trial
3. having severe complications
4. having severe mental disorders

Target sample size

56


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Haruo Sugiyama

Organization

Osaka University Graduate School of Medicine

Division name

Dept Functional Diagnostic Science

Zip code


Address

1-7 Yamada-oka Suita city Osaka, Japan

TEL

06-6879-2597

Email

sugiyama@sahs.med.osaka-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yusuke Oji

Organization

Osaka University Graduate School of Medicine

Division name

Cancer Stem Cell Biology

Zip code


Address

1-7 Yamada-oka Suita city Osaka, Japan

TEL

06-6879-2597

Homepage URL

http://sahswww.med.osaka-u.ac.jp/~hmtonc/vaccine/index.htm

Email

oji@sahs.med.osaka-u.ac.jp


Sponsor or person

Institute

Osaka University Graduate Shool of Medicine,
Functional Diagnostic Science

Institute

Department

Personal name



Funding Source

Organization

MEXT(Japan)

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)

Non-pharmaceutical companies


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪大学医学部附属病院


Other administrative information

Date of disclosure of the study information

2014 Year 12 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 02 Month 14 Day

Date of IRB

2014 Year 02 Month 19 Day

Anticipated trial start date

2014 Year 12 Month 24 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 12 Month 18 Day

Last modified on

2024 Year 03 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018592


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name